Tag: Medullary Thyroid Cancer

Home / Medullary Thyroid Cancer

Categories

Selpercatinib is approved by the USFDA for medullary thyroid cancer with a RET mutation

 On September 27, 2024, the Food and Drug Administration conferred traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients aged 2 years and older diagn...
medullary-thyroid-cancer

Scan the code